Leveraging Government support and global partnerships to increase
biologics manufacturing capacity
Leveraging Government support and global partnerships to increase biologics manufacturing capacity
What is BPA’s mission?
• fill key national capability gap in biologics development • deliver key element to Smart State 10 year biotech strategy• devise business model • raise funds to support the model• identify commercial partner• design and build facility to commercial partner’s specs
The capability gap Leveraging Government support and global partnerships
to increase biologics manufacturing capacity
The Business Model
• partner with Contract Manufacturing Organisation (CMO) • public funded capital infrastructure : industry attraction • design and build to CMO’s user requirement• landlord-tenant relationship• CMO has full autonomy in commercial operation• BPA has transitional support function for 2-3 years
Leveraging Government support and global partnerships to increase biologics manufacturing capacity
Q - Why a CMO model? A - a clear market trend over 5+ yrs
• Time-to-market pressure• Offset risk – test the market first• Spare capital during clinical development• Allow developers to focus on areas of strength
• IP generation• Clinical trials• Marketing and distribution
Leveraging Government support and global partnerships to increase biologics manufacturing capacity
BPA’s partnering methodology
• develop value proposition• leverage complementary clinical development providers• invite expressions of interest from CMO’S worldwide• request for proposals from selected group• evaluation of bids against set criteria• offer Terms Sheet to DSM Biologics
Leveraging Government support and global partnerships to increase biologics manufacturing capacity
Strategic investment in biopharmaceutical manufacturing – a Queensland case study
Why DSM Biologics?
• Track record• Financial stability• Commercial focus• No product IP – 100% customer service focus• Technology and commercial differentiators
Quick history
• Dec 2009 - BPA signs Terms Sheet with DSM Biologics• 2010 - concept design underway; negotiation of lease• 2010 - building shell underway• 2011 - completion of facility design and tender package• Jan 2012 - internal fit out underway
Snapshot of the future
• 2012 - complete fit out; procure process equipment• Jan 2013 - commissioning and qualification• Operations commence – July 2013
Leveraging Government support and global partnerships to increase biologics manufacturing capacity
Leverage other service providers:AIBN key linkage
Top Related